Short report: Q fever pneumonia: Are clarithromycin and moxifloxacin alternative treatments only?

被引：10
作者：
Morovic, N [1 ]
机构：
[1] Zadar Gen Hosp, Dept Infect Dis, Zadar 23000, Croatia
来源：
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2005年 / 73卷 / 05期
关键词：
D O I：
10.4269/ajtmh.2005.73.947
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Medical records of 77 patients with Q fever pneumonia that was serologically confirmed by enzyme-linked immunosorbent assay were studied to compare the clinical efficacy of doxycycline, clarithromycin, and moxifloxacin. The mean times to defervescence were 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin. There were no interruptions of the regimens in any groups because of side effects, and outcome was favorable in all patients with no complications or relapses during follow-up. This efficacy of clarithromycin and moxifloxacin, together with their safety profiles, suggest that these alternative agents in the treatment of Q fever pneumonia could also be used as the first-line therapy.
引用
收藏
页码：947 / 948
页数：2
相关论文
共 14 条
[1]  
Dumler J. S., 2002, Current Treatment Options in Infectious Diseases, V4, P437
[2]  
Dzelalija B, 1990, Lijec Vjesn, V112, P102
[3]   International guidelines for the treatment of community-acquired pneumonia in adults - The role of Macrolides [J].
File, TM ;
Tan, JS .
DRUGS, 2003, 63 (02) :181-205
[4]   In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin [J].
Gikas, A ;
Spyridaki, I ;
Psaroulaki, A ;
Kofterithis, D ;
Tselentis, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2747-2748
[5]   Newer macrolides as empiric treatment for acute Q fever infection [J].
Gikas, A ;
Kofteridis, DP ;
Manios, A ;
Pediaditis, J ;
Tselentis, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3644-3646
[6]   In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin [J].
Gikas, A ;
Spyridaki, I ;
Scoulica, E ;
Psaroulaki, A ;
Tselentis, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3276-3278
[7]   Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens [J].
Hoeffken, G ;
Talan, D ;
Larsen, LS ;
Peloquin, S ;
Choudhri, SH ;
Haverstock, D ;
Jackson, P ;
Church, D .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (10) :772-775
[8]   In vitro susceptibility of Coxiella burnetti to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones [J].
Lever, MS ;
Bewley, KR ;
Dowsett, B ;
Lloyd, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (02) :194-196
[9]   Q fever pneumonia [J].
Marrie, TJ .
CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (02) :137-142
[10]   PHAGOLYSOSOMAL ALKALINIZATION AND THE BACTERICIDAL EFFECT OF ANTIBIOTICS - THE COXIELLA-BURNETII PARADIGM [J].
MAURIN, M ;
BENOLIEL, AM ;
BONGRAND, P ;
RAOULT, D .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) :1097-1102
12